NEXT, Virginia
Clinical research site in Fairfax, Virginia · 12011 GOVERNMENT CENTER PKWY, SUITE 836, FAIRFAX, VA 22035-1100 · (703) 324-7000 · Website
As of September 2026, 82 paid clinical trials are recruiting at NEXT, Virginia in Fairfax, Virginia. Active studies at this site cover conditions such as Advanced Solid Tumor, Advanced Solid Tumors and Solid Tumor. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at NEXT, Virginia (82)
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
A Study of LY4175408 in Participants With Advanced Cancer
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
Study of XB010 in Subjects With Solid Tumors
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
A Study of PYX-201 in Advanced Solid Tumors
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Study of SGR-3515 In Participants With Advanced Solid Tumors.
Study of AVZO-021 in Patients With Advanced Solid Tumors
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
A Study of HLD-0117 in Patients With Metastatic Breast Cancer
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Showing the 40 most relevant of 82 recruiting trials at this site. Browse all with filters →
Get new-trial alerts for NEXT, Virginia
We'll email you whenever a new clinical trial starts recruiting at this research site in Fairfax, VA. Unsubscribe anytime.
More research sites in Fairfax
- NEXT Virginia (74 trials)
- Virginia Cancer Specialists (65 trials)
- Inova Schar Cancer Institute (56 trials)
- NEXT Oncology Virginia (28 trials)
- NEXT Oncology (24 trials)
- Virginia Cancer Specialists, PC (15 trials)
- Inova Fair Oaks Hospital (13 trials)
- Re:Cognition Health (7 trials)
- Inova Schar Cancer (7 trials)
- Inova Fairfax Hospital (6 trials)
Is this your research site?
This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.
Explore more
Paid clinical trials in Fairfax, VA · Virginia clinical trials